Electrocardiogram and cardiovascular changes in thioridazine and chlorpromazine poisoning

European Journal of Clinical Pharmacology

Volumn 60, Issue 8, 2004, Pages 541-545

  Strachan, E M ^a   Kelly, C A ^a   Bateman, D N ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; PERPHENAZINE; PIMOZIDE; PROCHLORPERAZINE; PROMAZINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; TRIFLUOPERAZINE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR PARAMETERS; CLINICAL EXAMINATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG INTOXICATION; DRUG OVERDOSE; ELECTROCARDIOGRAM; EVALUATION; FEMALE; HEART RATE; HUMAN; INGESTION; MALE; MEDICAL RECORD; PRIORITY JOURNAL; PULSE PRESSURE; QT PROLONGATION;

ADULT; ANTIPSYCHOTIC AGENTS; BLOOD PRESSURE; CHLORPROMAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; ENGLAND; FEMALE; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS; MALE; MEDICAL RECORDS; POISONING; RETROSPECTIVE STUDIES; THIORIDAZINE;

EID: 8744288400     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-004-0811-7     Document Type: Article

References (24)

1. Roden DM (2004) Drug induced prolongation of the QT interval. N Engl J Med 350:1013-1022
2. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SHL (2000) QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 355:1048-1052
3. Haddad PM, Anderson IM (2002) Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 62:1649-1671
4. Taylor DM (2003) Antipsychotics and QT prolongation. Acta Psychiatr Scand 107:85-95
5. Bateman DN, Good AM, Afshari R, Kelly CA (2003) Effects of licence change on prescribing and poisons enquires for antipsychotic agents in England and Scotland. Br J Clin Pharmacol 55:596-693
6. Davies SJC, Cooke LB, Moore AG, Potokar J (2002) Discontinuation of thioridazine in patients with learning disabilities: balancing cardiovascular toxicity with adverse consequences of changing drugs. Br Med J 324:1519-1521
7. Czekalla J, Kollack-Walker S, Beasley CM (2001) Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. J Clin Psychiatry 62(suppl2):35-40
8. Hulisz DT, Dasa SL, Black LD, Heiselman DE (1994) Complete heart block and torsade de pointes associated with thioridazine poisoning. Pharmacotherapy 14:239-245
9. Gury C, Canceil O, Iaria P (2000) Antipsychotic drugs and cardiovascular safety: current study of prolonged QT interval and risk of ventricular arrhythmia. Encephale 26:62-72
10. Stramba-Badiale M, Locati EH, Martinelli A, Courville J, Schwartz PJ (1997) Gender and the relationship between ventricular repolarisation and the cardiac cycle length during 24-h Holter recordings. Eur Heart J 18:1000-1006
11. De Ponti F, Poluzzi E, Montanaro N (2000) Qt-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol 56:1-18
12. Bril A, Gout B, Bonhomme M, Landais L, Faivre J, Linee P, Poyser RH, Ruffolo RR (1996) Combined potassium and calcium channel blocking activities as a basis for arythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872. J Pharmacol Exp Ther 276:637-646
13. Goodnick PJ, Parra F, Jerry J (2002) Psychotropic drugs and the ECG: focus on the QTc interval. Expert Opin Pharmacother 3:479-498
14. MCA/CSM (2001) QTc prolongation with antipsychotics. Curr Probl 27:4
15. Warner JP, Barnes TR, Henry JA, (1996) Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatr Scand 93:311-313
16. Good AM, Strachan F, Oliver J, Kelly CA, Bateman DN (2002) Licensing decisions and TOXBASE® - evaluating the effect of restricted indications for thioridazine on its use in acute overdose. J Clin Pharmacol 53:416-417
17. Drolet B, Vincent F, Rail J, Chahine M, Deschenes D, Nadeau S, Khalifa M, Hamelin BA, Turgeon J (1999) Thioridazine lengthens repolarisation of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. J Pharmacol Exp Ther 288:1261-1268
18. Fowler NO, McCall D, Chou TC, Holmes JC, Hanenson IB (1976) Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs. Am J Cardiol 37:223-230
19. Hartington-Go K, Bateman DN, Nyberg G, Martensson E, Thomas SHL (1996) Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther 60:543-553
20. Hale P, Poklis A (1996) Thioridazine cardiotoxicity. Clin Toxicol 34:127-128
21. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SHL (2002) Thioridazine and sudden unexplained death in psychiatric inpatients. Br J Psychiatry 180:515-522
22. Buckley NA, Whyte IM, Dawson AH (1995) Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. J Toxicol Clin Toxicol 33:199-204
23. Mortensen PB, Juel K (1993) Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry 163:183-189
24. Belardinelli L, Antzelevitch C, Vos MA (2003) Assessing predictors of drug induced torsade de pointes. TIPS 24:619-625